AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20216060 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training on a bicycle ergometer and balance exercise (Training Group 1)
Number of subjects: 45
Study 20216060 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based lower‐limb strengthening and balance exercise (Training Group 2)
Number of subjects: 45
Study 20216060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 17266764 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily
Number of subjects: 3235
Study 17266764 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg once daily with initial dose of 200 mg for the first 2 weeks
Number of subjects: 3235
Study 17266764 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 3235
Study 17266764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3235
Study 15226138 — intervention group
Group type: EXPERIMENTAL
Intervention: Woman-focused intervention
Number of subjects: 620
Study 15226138 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised National Institute on Drug Abuse standard intervention
Number of subjects: 620
Study 15226138 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 620
Study 11910315 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 34
Study 11910315 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 34
Study 11910315 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 34
Study 11910315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 34
Study 11910315 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 34
Study 11910315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9814466 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection (PEI)
Number of subjects: 41
Study 7745464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical devices (e.g., graduated leg stockings; external pneumatic calf compression)
Number of subjects: 0
Study 7745464 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological agents (e.g., low dose heparin)
Number of subjects: 0
Study 7745464 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins and heparinoids
Number of subjects: 0
Study 2643933 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 0.5 mg/kg/d
Number of subjects: 43
Study 2643933 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 1.5 mg/kg/d
Number of subjects: 43
Study 2643933 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 3 mg/kg/d
Number of subjects: 43
Study 2643933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 1092731 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 400 mg daily
Number of subjects: 28
Study 1092731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29439405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (5000 IU/day)
Number of subjects: 60
Study 29439405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28165591 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxima™ ultra‐short uncemented stem
Number of subjects: 25
Study 25310394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Total Disk Replacement (Mobi-C Cervical Disc Prosthesis)
Number of subjects: 245
Study 25310394 — intervention group
Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Number of subjects: 245
Study 24192245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein repair
Number of subjects: 282
Study 24192245 — intervention group
Group type: COMPARATOR
Intervention: Onstep approach
Number of subjects: 282
Study 21493191 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight Assistant (HWA) intervention
Number of subjects: 297
Study 21493191 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 297
Study 19107337 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal acidification (0.1 N HCl, 20 ml/min for 5 min)
Number of subjects: 14
Study 19107337 — intervention group
Group type: COMPARATOR
Intervention: Pure water infusion (20 ml/min for 5 min)
Number of subjects: 14
Study 16449540 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release tacrolimus (MR-4)
Number of subjects: 0
Study 14521639 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (N = 112)
Number of subjects: 226
Study 14521639 — intervention group
Group type: COMPARATOR
Intervention: Internet group (N = 114)
Number of subjects: 226
Study 14521639 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 226
Study 10999643 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with a focus on maintaining diastolic blood pressure (DBP) above mid- to low 80s.
Number of subjects: 0
Study 10999643 — intervention group
Group type: COMPARATOR
Intervention: Control group with DBP not lowered below mid- to low 80s.
Number of subjects: 0
Study 8644831 — intervention group
Group type: EXPERIMENTAL
Intervention: Added-materials condition
Number of subjects: 21
Study 8644831 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-based condition
Number of subjects: 21
Study 8644831 — intervention group
Group type: COMPARATOR
Intervention: Rote exercise condition
Number of subjects: 21
Study 1937790 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella typhi Ty21a vaccine (10^9 CFU per dose, three doses)
Number of subjects: 18
Study 6341435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insufflation of 50 mg of dry ragweed or timothy grass pollen (antigen challenge)
Number of subjects: 8
Study 6341435 — intervention group
Group type: COMPARATOR
Intervention: Insufflation of pine pollen (control)
Number of subjects: 8
Study 31436325 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MRI parameters
Number of subjects: 133
Study 31436325 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 133
Study 31436325 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of chemoradiotherapy (CRT)
Number of subjects: 133
Study 31436325 — intervention group
Group type: EXPERIMENTAL
Intervention: Final multivariable model including significant variables
Number of subjects: 133
Study 29273929 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cultured fibroblasts
Number of subjects: 46
Study 29273929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26735646 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater family cohesion and flexibility
Number of subjects: 472
Study 26735646 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater self-efficacy
Number of subjects: 472
Study 26735646 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher self-efficacy
Number of subjects: 472
Study 26735646 — intervention group
Group type: EXPERIMENTAL
Intervention: Openness
Number of subjects: 472
Study 25373830 — intervention group
Group type: EXPERIMENTAL
Intervention: Unleaded ammunition
Number of subjects: 55
Study 25373830 — intervention group
Group type: COMPARATOR
Intervention: Leaded ammunition
Number of subjects: 55
Study 25373830 — intervention group
Group type: COMPARATOR
Intervention: Modified unleaded ammunition
Number of subjects: 55
Study 22607553 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior centre group programme (weekly meetings)
Number of subjects: 138
Study 22607553 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 138
Study 20847709 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 13
Study 20847709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (rapamycin)
Number of subjects: 13
Study 20847709 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 13
Study 20847709 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 13
Study 20847709 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 13
Study 17054896 — intervention group
Group type: EXPERIMENTAL
Intervention: 350‐mm(2) Baerveldt glaucoma implant
Number of subjects: 212
Study 17054896 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (MMC)
Number of subjects: 212
Study 17054896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 212
Study 16295223 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced laryngeal mask airway (LMA) anesthesia
Number of subjects: 146
Study 16295223 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (El) anesthesia
Number of subjects: 146
Study 11932320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant 20 mg/d for 7 d
Number of subjects: 6
Study 11932320 — intervention group
Group type: COMPARATOR
Intervention: Octreotide 50 microg thrice daily for 7 d
Number of subjects: 6
Study 11196128 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Pass Resolution Perimetry (HRP)
Number of subjects: 68
Study 7502230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic plus para‐aortic lymph nodes irradiation (para‐aortic group)
Number of subjects: 93
Study 7502230 — intervention group
Group type: COMPARATOR
Intervention: Pelvic irradiation (pelvic group)
Number of subjects: 93
Study 7502230 — intervention group
Group type: EXPERIMENTAL
Intervention: Para‐aortic group
Number of subjects: 93
Study 7502230 — intervention group
Group type: COMPARATOR
Intervention: Pelvic group
Number of subjects: 93
Study 1724116 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg daily for 2 weeks)
Number of subjects: 30
Study 1724116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7130400 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 12
Study 7130400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29373060 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressive Myofascial Release (CMR)
Number of subjects: 44
Study 29373060 — intervention group
Group type: COMPARATOR
Intervention: Graston Technique (GT)
Number of subjects: 44
Study 29373060 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 26031460 — intervention group
Group type: EXPERIMENTAL
Intervention: MLN3897 (CP moiety)
Number of subjects: 12
Study 26031460 — intervention group
Group type: EXPERIMENTAL
Intervention: MLN3897 (TC moiety)
Number of subjects: 12
Study 23527873 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual handrim wheelchair
Number of subjects: 15
Study 23527873 — intervention group
Group type: EXPERIMENTAL
Intervention: Lever drive wheelchair
Number of subjects: 15
Study 23527873 — intervention group
Group type: EXPERIMENTAL
Intervention: Neater Uni-wheelchair (NUW)
Number of subjects: 15
Study 22691058 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive application of locally delivered minocycline ointment in association with flap surgery (FM)
Number of subjects: 20
Study 22691058 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery only (FO)
Number of subjects: 20
Study 19875102 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cognitive skills workbook
Number of subjects: 0
Study 19875102 — intervention group
Group type: COMPARATOR
Intervention: Non-traditional cognitive skills workbook
Number of subjects: 0
Study 19875102 — intervention group
Group type: COMPARATOR
Intervention: Academic skills workbook
Number of subjects: 0
Study 19264565 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-incisional infiltration with levobupivacaine
Number of subjects: 50
Study 19264565 — intervention group
Group type: COMPARATOR
Intervention: Post-operative infiltration with levobupivacaine
Number of subjects: 50
Study 16437375 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (30 g/d) for 7 days
Number of subjects: 39
Study 16437375 — intervention group
Group type: COMPARATOR
Intervention: Control (no glutamine)
Number of subjects: 39
Study 15215812 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) therapy
Number of subjects: 312
Study 15215812 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 312
Study 15215812 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK therapy
Number of subjects: 312
Study 15215812 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK therapy (in diabetic patients)
Number of subjects: 312
Study 10902791 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens started at age 15 years
Number of subjects: 60
Study 10902791 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens started at age 12 years
Number of subjects: 60
Study 10902791 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy before estrogen treatment
Number of subjects: 60
Study 10902791 — intervention group
Group type: COMPARATOR
Intervention: Historical control patients (age-matched)
Number of subjects: 60
Study 8888720 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg at night
Number of subjects: 23
Study 8888720 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg in the morning
Number of subjects: 23
Study 8888720 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg at night and omeprazole 20 mg in the morning
Number of subjects: 23
Study 1546823 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal provocation (allergen-induced nasal reactivity)
Number of subjects: 27
Study 1546823 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat nasal challenges
Number of subjects: 27
Study 1546823 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific nasal challenge
Number of subjects: 27
Study 3906942 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (400 mg)
Number of subjects: 80
Study 3906942 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (1.5 mg/kg)
Number of subjects: 80
Study 3305488 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80, 160, or 320 mg/day)
Number of subjects: 212
Study 3305488 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (30, 45, or 75 mg/day)
Number of subjects: 212
Study 3305488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 28762135 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily
Number of subjects: 11
Study 28762135 — intervention group
Group type: COMPARATOR
Intervention: Everolimus 5 mg twice daily
Number of subjects: 11
Study 27582675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (1 intravitreal bevacizumab injection 1.25 mg + PDT)
Number of subjects: 62
Study 27582675 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab monotherapy
Number of subjects: 62
Study 24697819 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine alone
Number of subjects: 24
Study 24697819 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine plus midazolam
Number of subjects: 24
Study 22544804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF 300 mg once daily for 72 weeks
Number of subjects: 106
Study 22544804 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 72 weeks
Number of subjects: 106
Study 19760359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet intervention (MeDiet)
Number of subjects: 1048
Study 18442423 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion (CPM) + Physiotherapy (PT) for 17 consecutive days after surgery
Number of subjects: 60
Study 18442423 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (PT) alone after usual care in the first two weeks post-discharge
Number of subjects: 60
Study 15721096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 0
Study 15721096 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir
Number of subjects: 0
Study 14502837 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological awareness tasks adapted from literature
Number of subjects: 9
Study 10707917 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription NSAIDs
Number of subjects: 11898
Study 10707917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (dosages < or =1,200 mg/day)
Number of subjects: 11898
Study 10707917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (dosages >1,200-<2,400 mg/day)
Number of subjects: 11898
Study 10707917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (dosages > or =2,400 mg/day)
Number of subjects: 11898
Study 10707917 — intervention group
Group type: COMPARATOR
Intervention: Population controls (no NSAID use)
Number of subjects: 11898
Study 9195347 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg i.v. lidocaine 90 seconds prior to endotracheal intubation
Number of subjects: 60
Study 9195347 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study 1287615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF (750 mg)
Number of subjects: 40
Study 1287615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF (500 mg) alone
Number of subjects: 40
Study 1287615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF with cimetidine
Number of subjects: 40
Study 1287615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF with Maalox TC
Number of subjects: 40
Study 1287615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor immediate release (500 mg) alone
Number of subjects: 40
Study 3519451 — intervention group
Group type: EXPERIMENTAL
Intervention: CL 115347 (prostaglandin E2 analogue)
Number of subjects: 26
Study 3519451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 30632023 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 666
Study 30632023 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 666
Study 30620870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual Zinc plus Arginine dentifrice
Number of subjects: 80
Study 30620870 — intervention group
Group type: COMPARATOR
Intervention: Regular fluoride dentifrice
Number of subjects: 80
Study 28639860 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Conconi test (CT)
Number of subjects: 12
Study 28639860 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exercise test (PET)
Number of subjects: 12
Study 25350539 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional intervention (trained research assistant provided distraction)
Number of subjects: 574
Study 25350539 — intervention group
Group type: COMPARATOR
Intervention: Basic intervention (parents trained on providing distraction)
Number of subjects: 574
Study 25350539 — intervention group
Group type: COMPARATOR
Intervention: Enhanced intervention (basic training plus tailored instructions, environmental modifications, and support)
Number of subjects: 574
Study 23883636 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (60-minute comprehensive exercise program, twice a week for 3 months)
Number of subjects: 155
Study 23883636 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + amino acid supplementation (6 g/day for 3 months)
Number of subjects: 155
Study 23883636 — intervention group
Group type: COMPARATOR
Intervention: Amino acid supplementation (6 g/day for 3 months)
Number of subjects: 155
Study 23883636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 155
Study 21046171 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 100 mg once daily
Number of subjects: 37
Study 18029066 — intervention group
Group type: EXPERIMENTAL
Intervention: Study vaccine (Group 1)
Number of subjects: 296
Study 18029066 — intervention group
Group type: COMPARATOR
Intervention: Vero cells vaccine (Group 2)
Number of subjects: 296
Study 18029066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 296
Study 16271155 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroid treatment (fluticasone) for 4 weeks
Number of subjects: 42
Study 16271155 — intervention group
Group type: COMPARATOR
Intervention: Nasal biopsies from patients with allergic rhinitis
Number of subjects: 42
Study 16271155 — intervention group
Group type: COMPARATOR
Intervention: Nasal biopsies from healthy volunteers
Number of subjects: 42
Study 16271155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal polyps
Number of subjects: 42
Study 12114411 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 administered once daily at a dose of 50 mg/m2/day for 21 consecutive days
Number of subjects: 18
Study 12114411 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 administered once daily at a dose of 60 mg/m2/day for 21 consecutive days
Number of subjects: 18
Study 12114411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic analysis of S-1
Number of subjects: 18
Study 12114411 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of diarrhea grade with pharmacokinetics
Number of subjects: 18
Study 11123415 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel barrier/repair cream
Number of subjects: 80
Study 11123415 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum-based cream
Number of subjects: 80
Study 8737631 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/d HR
Number of subjects: 137
Study 8737631 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg/d and 500 mg/d HR
Number of subjects: 137
Study 8737631 — intervention group
Group type: COMPARATOR
Intervention: 600 mg/d HCE
Number of subjects: 137
Study 1327655 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (oral administration)
Number of subjects: 13
Study 1327655 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 13
Study 3994782 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance physical training (4 months, 3 times/week for 1-hour sessions)
Number of subjects: 10
Study 3994782 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 patients with similar characteristics)
Number of subjects: 10
Study 31110092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifamurtide combined with postoperative chemotherapy
Number of subjects: 126